Obstetrical, Endocrine and Metabolic Consequences of Antenatal Dexamethasone Treatment in Pregnant Women at Risk of Congenital Adrenal Hyperplasia

What this Trial Is About

This research aims to analyze obstetric, endocrine, and metabolic follow-up data in women treated with dexamethasone (DEX) during pregnancy who are at risk of congenital adrenal hyperplasia. It seeks to understand the occurrence and impact of weight gain, insomnia, edema, stretch marks, arterial hypertension, and gestational diabetes. The study also evaluates pregnancy outcomes and assesses the corticotropic axis during and up to three months after pregnancy to improve management and prevent related health issues. The study includes women treated with DEX during pregnancy, focusing on those with a severe mutation of the CYP21A2 gene in both parents and carrying a female single fetus. Participants have started prenatal DEX treatment for at least 24 hours. This observational study collects retrospective and prospective data from this group to evaluate the effects and outcomes of the treatment. Participants will be monitored through follow-up data collection, including metabolic complications like hypertension and diabetes, adverse effects such as weight gain and insomnia, pregnancy complications, and hormone levels (cortisol and S-DHEA) during and after treatment. The primary outcome is the proportion of mothers developing hypertension and/or diabetes over an average of four years. The study aims to guide better clinical practices and recommendations for managing pregnant women treated with DEX.

Dexamethasone and Pregnancy: Maternal Effects